JPM vs MRSH
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
MRSH demonstrates stable operational health with a Piotroski F-Score of 6/9 and a strong ROE of 27.57%, yet it trades at a massive premium to its Graham Number ($73.7) and Intrinsic Value ($55.93). While the company has an exceptional 25-quarter track record of beating earnings estimates, recent YoY earnings growth has contracted by 15.4%. Bearish insider activity, specifically from the CEO, and a 0/100 technical trend suggest significant short-term headwinds despite a 'Buy' analyst consensus. The stock is a high-quality business currently suffering from a valuation disconnect and decelerating earnings momentum.
Compare Another Pair
Related Comparisons
JPM vs MRSH: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and Marsh & McLennan Companies, Inc. (MRSH) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.